The Long-Term Neuroprotective Effect of the Endocannabinoid 2-AG and Modulation of the SGZ's Neurogenic Response after Neonatal Hypoxia-Ischemia.
2-AG
endocannabinoid system
neonatal hypoxia-ischemia
neurogenesis
neuroprotection
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
07 Jun 2023
07 Jun 2023
Historique:
received:
10
04
2023
revised:
25
05
2023
accepted:
02
06
2023
medline:
28
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
Neonatal hypoxia-ischemia (HI) often causes hypoxic-ischemic encephalopathy (HIE), a neurological condition that can lead to overall disability in newborns. The only treatment available for affected neonates is therapeutic hypothermia; however, cooling is not always effective to prevent the deleterious effects of HI, so compounds such as cannabinoids are currently under research as new therapies. Modulating the endocannabinoid system (ECS) may reduce brain damage and/or stimulate cell proliferation at the neurogenic niches. Further, the long-term effects of cannabinoid treatment are not so clear. Here, we studied the middle- and long-term effects of 2-AG, the most abundant endocannabinoid in the perinatal period after HI in neonatal rats. At middle-term (postnatal day 14), 2-AG reduced brain injury and increased SGZ's cell proliferation and the number of neuroblasts. At post-natal day 90, the treatment with the endocannabinoid showed global and local protection, suggesting long-lasting neuroprotective effects of 2-AG after neonatal HI in rats.
Identifiants
pubmed: 37376115
pii: pharmaceutics15061667
doi: 10.3390/pharmaceutics15061667
pmc: PMC10300731
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : EITB Maratoia-BIOEF
ID : BIO18/IC/003
Organisme : MCIN/AEI/10.13039/501100011033
ID : MINECOR20/P66
Organisme : "Programa Investigo" by the European Union-Next Generation EU
ID : PIFINVE22/15
Références
Neurosci Bull. 2011 Aug;27(4):275-85
pubmed: 21788999
Arch Dis Child Fetal Neonatal Ed. 1996 Jan;74(1):F3-9
pubmed: 8653432
Mol Neurobiol. 2017 Sep;54(7):5300-5318
pubmed: 27578020
J Neurosci. 2014 Apr 23;34(17):5788-99
pubmed: 24760839
Biol Psychiatry. 2016 Apr 1;79(7):516-25
pubmed: 26698193
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
BMC Neurosci. 2005 Mar 02;6:15
pubmed: 15743533
Biochem Pharmacol. 1995 Jun 29;50(1):83-90
pubmed: 7605349
Science. 1992 Dec 18;258(5090):1946-9
pubmed: 1470919
Pediatr Res. 2011 Jan;69(1):51-5
pubmed: 20856166
Pediatr Neurol. 2014 Jul;51(1):104-8
pubmed: 24810874
Brain Res. 2010 Nov 29;1362:150-9
pubmed: 20858469
J Mol Med (Berl). 2001;78(11):613-25
pubmed: 11269508
Stroke. 2017 Jan;48(1):204-212
pubmed: 27899748
Pediatr Res. 2012 Oct;72(4):400-6
pubmed: 22821058
Neurogenesis (Austin). 2016;3(1):
pubmed: 27468423
Sci Rep. 2017 Mar 10;7:44111
pubmed: 28281676
Brain Res. 2012 Sep 20;1474:91-9
pubmed: 22841538
Pediatr Res. 2007 Sep;62(3):255-60
pubmed: 17622949
Neurotherapeutics. 2015 Oct;12(4):793-806
pubmed: 26260390
Life (Basel). 2022 Jul 30;12(8):
pubmed: 36013343
Neuron. 2014 Mar 5;81(5):1097-1110
pubmed: 24508384
J Exp Biol. 2004 Aug;207(Pt 18):3149-54
pubmed: 15299036
Handb Clin Neurol. 2019;162:217-237
pubmed: 31324312
Pediatr Res. 1998 Jun;43(6):738-45
pubmed: 9621982
Neurotox Res. 2018 Aug;34(2):188-197
pubmed: 29427282
Histol Histopathol. 2012 Jun;27(6):771-83
pubmed: 22473697
Brain Res Dev Brain Res. 1997 Jun 18;100(2):149-60
pubmed: 9205806
Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):2074-7
pubmed: 8446631
Nature. 2006 Aug 24;442(7105):929-33
pubmed: 16906136
Elife. 2015 Oct 17;4:e08722
pubmed: 26476335
Neurotox Res. 2022 Dec;40(6):1690-1706
pubmed: 36522511
J Neurosci. 2008 Nov 5;28(45):11511-6
pubmed: 18987187
Cells. 2020 Aug 03;9(8):
pubmed: 32756411
Am J Perinatol. 2000;17(3):113-20
pubmed: 11012134
FASEB J. 2006 Nov;20(13):2405-7
pubmed: 17015409
Curr Opin Pharmacol. 2020 Feb;50:25-32
pubmed: 31864101
J Neurosci. 1999 Apr 15;19(8):2987-95
pubmed: 10191316
Front Neuroanat. 2015 Dec 23;9:161
pubmed: 26778970
Front Pediatr. 2022 Apr 28;10:793189
pubmed: 35573964
Front Aging Neurosci. 2022 Jul 27;14:925728
pubmed: 35966788
Biochem Pharmacol. 2018 Nov;157:85-96
pubmed: 30118663
Ann Neurol. 1981 Feb;9(2):131-41
pubmed: 7235629
Pediatr Res. 2015 Sep;78(3):264-71
pubmed: 25996893
Nat Med. 1998 Nov;4(11):1313-7
pubmed: 9809557
Neurobiol Dis. 2010 May;38(2):259-65
pubmed: 20117210
J Biol Chem. 2007 Aug 17;282(33):23892-8
pubmed: 17556369
Stroke. 2010 Dec;41(12):2956-64
pubmed: 21115947
Science. 2001 Dec 7;294(5549):2127-30
pubmed: 11739948
Nature. 2013 May 16;497(7449):369-73
pubmed: 23615612
Biochem Biophys Res Commun. 1995 Oct 4;215(1):89-97
pubmed: 7575630
Neurochem Res. 2012 Jan;37(1):161-70
pubmed: 21909954
Pharmacology. 2012;90(1-2):19-39
pubmed: 22776780
Mol Pharmacol. 1998 Sep;54(3):459-62
pubmed: 9730904
Curr Neurol Neurosci Rep. 2019 Jan 14;19(2):2
pubmed: 30637551
Early Hum Dev. 2010 Jun;86(6):329-38
pubmed: 20554402
Neuron. 2004 Mar 4;41(5):683-6
pubmed: 15003168
Inflamm Regen. 2023 Apr 17;43(1):24
pubmed: 37069694
J Cereb Blood Flow Metab. 2007 Feb;27(2):282-92
pubmed: 16736041